Skip to navigation Skip to content



About this Medication
  • Brand Name: Zeposia® (zeh-poe’-see-ah)
  • Chemical Name: ozanimod (oh-ZAN-i-mod)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This is an oral medication in capsule form.

*Release of Zeposia® postponed: As the country’s healthcare system is dealing with the unprecedented COVID-19 pandemic, Bristol Myers Squibb has made the decision to postpone the release of Zeposia, which they believe to be in the best interest of their patients, customers, and employees. They will continue to monitor the environment and partner with the healthcare community to determine when Zeposia will be made available.


Zeposia® is a sphingosine 1-phosphate receptor modulator, which is thought to act by retaining certain white blood cells (lymphocytes) in the lymph nodes, thereby preventing those cells from crossing the blood-brain barrier into the central nervous system (CNS). Preventing the entry of these cells into the CNS reduces inflammatory damage to nerve cells.

Zeposia was approved by the U.S. Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Click here to read the Zeposia Prescribing Information for healthcare professionals.

Click here to read the Zeposia Medication Guide for patients.


Bristol Myers Squibb

Financial Assistance Program

Financial assistance program information has not been released and will be published here when it is available.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.